Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.

Antimicrobial agents and chemotherapy - 1 Jan 2012

Visseaux Benoit, Charpentier Charlotte, Hurtado-Nedelec Margarita, Storto Alexandre, Antoine Romain, Peytavin Gilles, Damond Florence, Matheron Sophie, Brun-Vézinet Françoise, Descamps Diane

Abstract excerpt

HIV-2 is naturally resistant to nonnucleoside reverse transcriptase inhibitors, to a fusion inhibitor, and to some of the protease inhibitors. Maraviroc is the first drug of the new anti-CCR5 drug class and is effective only on CCR5-tropic (R5) HIV-1. No previous studies concerning HIV-2 susceptibility to maraviroc have been reported yet. We developed a phenotypic maraviroc susceptibility test using a peripheral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CCR5 Receptor Antagonists
Share to Cyclohexanes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Phytohemagglutinins

Share to Receptors, CCR5

Share to Receptors, CXCR4

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 22064539
DOI: 10.1128/AAC.05313-11
PMCID: PMC3256042

Genes

CCR5
CXCR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.PMID 22064539Read ↗

Maraviroc: a review of its use in HIV infection and beyond.Semantic proximity Read ↗

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.Semantic proximity Read ↗

In vitro phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study.Semantic proximity Read ↗

Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.Semantic proximity Read ↗

<i>In vitro</i> phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (Maraviroc): TROPI-CO studySemantic proximity Read ↗

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.Semantic proximity Read ↗

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.Semantic proximity Read ↗

Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.Semantic proximity Read ↗

Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5).Semantic proximity Read ↗

Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.Semantic proximity Read ↗

Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.Semantic proximity Read ↗

Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.